Article

Investigations on druggable gene mutations related to AML/ALL lineage genes in Advanced Phases of CML: Implications in patient-tailored therapy of blast crisis CML in TKI era

2024-09-09

Abstract excerpt

<h4>Background</h4> Chronic Myeloid Leukemia (CML) is a myeloproliferative stem cell malignancy. Chronic Phase CML (CP-CML) is treatable with overall survival equivalent to the general population. Nevertheless, a proportion of CP-CML progresses to the accelerated phase (AP-CML) and ultimately blast crisis (BC-CML), with the latter having an overall survival (OS) of 3-23 months, making it almost a fatal manifestati...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: bf9c3abe-7642-5d62-be8a-d9d6f309ac62
DOI: 10.1101/2024.09.08.24313260

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Investigations on druggable gene mutations related to AML/ALL lineage genes in Advanced Phases of CML: Implications in patient-tailored therapy of blast crisis CML in TKI eraDOI 10.1101/2024.09.08.24313260Read

Repositioning of FDA-approved anti-cancer drugs for fatal blast crisis CML by integrated high-throughput genomic and artificial intelligence-based drug discovery analyses of pan-leukemic genetic abnormalities: Implications in post-COVID-19 eraSemantic proximity Read

Clonal evolution and clinical implications of genetic abnormalities in blastic transformation of chronic myeloid leukaemia.Semantic proximity Read

Prognostic Factors and Clinical Outcomes in Patients with Blast Phase Chronic Myeloid Leukemia.Semantic proximity Read

Next-generation DNA sequencing identifies mutated FANCD2 Gene as a novel Biomarker for monitoring early disease progression and timely therapeutic interventions in advanced phase Chronic Myeloid Leukemia patientsSemantic proximity Read

Next-Generation DNA Sequencing Identifies Mutated FANCD2 Gene as a Novel Biomarker for Monitoring Early Disease Progression and Timely Therapeutic Interventions in Advanced Phase Chronic Myeloid Leukemia PatientsSemantic proximity Read

Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoringSemantic proximity Read

Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoringSemantic proximity Read

A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of casesSemantic proximity Read

Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoringSemantic proximity Read

Mutation accumulation in cancer genes relates to nonoptimal outcome in chronic myeloid leukemiaSemantic proximity Read

Targeting FLT3-TAZ signaling to suppress drug resistance in blast phase chronic myeloid leukemiaSemantic proximity Read

Investigations on Clinical Validation of mutated ANKRD36 as a Novel Molecular Biomarker for Monitoring Early Progression and Timely Therapeutic Interventions in Blast Crisis CMLSemantic proximity Read